We are live on ! Find out more
AMPH icon

Amphastar Pharmaceuticals

135 hedge funds and large institutions have $458M invested in Amphastar Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 58 increasing their positions, 39 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

49% more repeat investments, than reductions

Existing positions increased: 58 | Existing positions reduced: 39

11% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 18

4% more capital invested

Capital invested by funds: $442M → $458M (+$15.8M)

1% more funds holding

Funds holding: 134135 (+1)

0.3% less ownership

Funds ownership: 48.21%47.91% (-0.3%)

Holders
135
Holders Change
+1
Holders Change %
+0.75%
% of All Funds
2.92%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
20
Increased
58
Reduced
39
Closed
18
Calls
$221K
Puts
Net Calls
+$221K
Net Calls Change
+$221K
Name Holding Trade Value Shares
Change
Change in
Stake
BlackRock
1
BlackRock
New York
$119M -$1.95M -86,844 -1%
Vanguard Group
2
Vanguard Group
Pennsylvania
$47.5M +$807K +36,003 +2%
Dimensional Fund Advisors
3
Dimensional Fund Advisors
Texas
$39.3M +$516K +23,018 +1%
Federated Hermes
4
Federated Hermes
Pennsylvania
$30.1M +$2.63M +117,480 +9%
State Street
5
State Street
Massachusetts
$21.7M +$971K +43,343 +4%
Invesco
6
Invesco
Georgia
$17.7M -$5.51M -246,082 -22%
TA
7
Teachers Advisors
New York
$11.6M -$32.4K -1,444 -0.3%
Northern Trust
8
Northern Trust
Illinois
$9.68M +$7.89K +352 +0.1%
Geode Capital Management
9
Geode Capital Management
Massachusetts
$9.08M +$432K +19,277 +5%
Renaissance Technologies
10
Renaissance Technologies
New York
$9.02M +$2.95M +131,500 +42%
Bank of New York Mellon
11
Bank of New York Mellon
New York
$8.18M -$1.05M -46,748 -10%
Morgan Stanley
12
Morgan Stanley
New York
$7.68M +$3.81M +170,112 +83%
RCAMU
13
Rothschild & Co Asset Management US
Connecticut
$6.41M -$501K -22,364 -7%
UBS AM
14
UBS AM
Illinois
$6.04M +$166K +7,413 +3%
Principal Financial Group
15
Principal Financial Group
Iowa
$5.68M -$64.1K -2,863 -1%
CAM
16
Cortina Asset Management
Wisconsin
$5.39M -$1.56M -69,479 -21%
Wells Fargo
17
Wells Fargo
California
$5.23M -$302K -13,484 -5%
Nordea Investment Management
18
Nordea Investment Management
Sweden
$5.19M +$97.3K +4,343 +2%
MCM
19
Matarin Capital Management
New York
$4.53M +$1.27M +56,666 +34%
MAM
20
Martingale Asset Management
Massachusetts
$4.5M +$374K +16,692 +8%
ACM
21
Argent Capital Management
Missouri
$4.28M -$578K -25,800 -11%
Goldman Sachs
22
Goldman Sachs
New York
$4.23M +$1.83M +81,521 +65%
Ameriprise
23
Ameriprise
Minnesota
$3.9M -$1.26M -56,132 -23%
Charles Schwab
24
Charles Schwab
California
$3.87M -$69.4K -3,096 -2%
PPA
25
Parametric Portfolio Associates
Washington
$3.21M -$1.04M -46,495 -23%

AMPH Hedge Fund Activity: Q1 2019 in Review

135 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Amphastar Pharmaceuticals (AMPH) for Q1 2019, worth a combined $458M — up 3.6% from $442M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new AMPH positions and 18 closed out — a net gain of 2 holders — while 58 added to existing stakes and 39 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $3.81M. The largest seller was Invesco, cutting an estimated $5.51M.

  • 135 institutional investors held Amphastar Pharmaceuticals (AMPH) as of Q1 2019, up from 134 in Q4 2018.
  • Funds reported $458M of Amphastar Pharmaceuticals stock for Q1 2019, up 3.6% quarter-over-quarter.
  • 20 funds opened new Amphastar Pharmaceuticals positions in Q1 2019 and 18 closed out, a net change of +2 holders.
  • The largest Amphastar Pharmaceuticals buyer in Q1 2019 was Morgan Stanley, an estimated $3.81M added.
  • The largest Amphastar Pharmaceuticals seller in Q1 2019 was Invesco, an estimated $5.51M sold.

Based on aggregated 13F filings for Q1 2019.